| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CANCER STEM CELLS |
aCentre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom;
bDepartment of Pathology and
cNorthern Ireland Regional Department of Thoracic Surgery, Royal Group of Hospitals Trust, Belfast, United Kingdom
Key Words. Erythropoietin receptor • Non-small cell lung carcinoma • C20 Antibody • Heat shock proteins
Correspondence: Perry Maxwell, Ph.D., Department of Pathology, Institute of Pathology, Royal Group of Hospitals Trust, Grosvenor Road, Belfast BT12 6BA, United Kingdom. Telephone: +44 2890635074; Fax: +44 2890632763; e-mail: p.maxwell{at}qub.ac.uk
Received October 26, 2006;
accepted for publication November 8, 2006.
First published online in STEM CELLS EXPRESS November 16, 2006.
Immunohistochemical studies on formalin-fixed, paraffin-embedded (FFPE) tissue utilizing polyclonal antibodies form the cornerstone of many reports claiming to demonstrate erythropoietin receptor (EPOR) expression in malignant tissue. Recently, Elliott et al. (Blood 2006;107:1892–1895) reported that the antibodies commonly used to detect EPOR expression also detect non-EPOR proteins, and that their binding to EPOR was severely abrogated by two synthetic peptides based on the sequence of heat shock protein (HSP) 70, HSP70-2, and HSP70-5. We have investigated the specificity of the C20 antibody for detecting EPOR expression in non-small cell lung carcinoma (NSCLC) utilizing tissue microarrays. A total of 34 cases were available for study. Antibody absorbed with peptide resulted in marked suppression of cytoplasmic staining compared with nonabsorbed antibody. Four tumors that initially showed a membranous pattern of staining retained this pattern with absorbed antibody. Positive membranous immunoreactivity was also observed in 6 of 30 tumors that originally showed a predominantly cytoplasmic pattern of staining. Using the C20 antibody for Western blots, we detected three main bands, at 100, 66, and 59 kDa. Preincubation with either peptide caused abolition of the 66-kDa band, which contains non-EPOR sequences including heat shock peptides. These results call into question the significance of previous immunohistochemical studies of EPOR expression in malignancy and emphasize the need for more specific anti-EPOR antibodies to define the true extent of EPOR expression in neoplastic tissue.
This article has been cited by other articles:
|
|
 |
|
  K. M. Kirschner, P. Hagen, C. S. Hussels, M. Ballmaier, H. Scholz, and C. Dame The Wilms' tumor suppressor Wt1 activates transcription of the erythropoietin receptor in hematopoietic progenitor cells FASEB J, August 1, 2008; 22(8): 2690 - 2701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O. Arcasoy Erythropoiesis-Stimulating Agent Use in Cancer: Preclinical and Clinical Perspectives Clin. Cancer Res., August 1, 2008; 14(15): 4685 - 4690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Chabowska, M. Sulkowska, A. Chabowski, A. Wincewicz, M. Koda, and S. Sulkowski Erythropoietin and Erythropoietin Receptor in Colorectal Cancer International Journal of Surgical Pathology, July 1, 2008; 16(3): 269 - 276. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Pirker, R. A. Ramlau, W. Schuette, P. Zatloukal, I. Ferreira, T. Lillie, and J. F. Vansteenkiste Safety and Efficacy of Darbepoetin Alfa in Previously Untreated Extensive-Stage Small-Cell Lung Cancer Treated With Platinum Plus Etoposide J. Clin. Oncol., May 10, 2008; 26(14): 2342 - 2349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Smith Jr, M. S. Aapro, H. Ludwig, T. Pinter, M. Smakal, T. E. Ciuleanu, L. Chen, T. Lillie, and J. A. Glaspy Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study J. Clin. Oncol., March 1, 2008; 26(7): 1040 - 1050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Henke and F. Pajonk In Reply J. Clin. Oncol., September 20, 2007; 25(27): 4326 - 4327. [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Blau Erythropoietin in Cancer: Presumption of Innocence? Stem Cells, August 1, 2007; 25(8): 2094 - 2097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. J. Lappin, A. P. Maxwell, and P. G. Johnston In Reply Oncologist, August 1, 2007; 12(8): 1032 - 1034. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gao, M. Boucher, J. K. Chuprun, R.-H. Zhou, A. D. Eckhart, and W. J. Koch Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H60 - H68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Lappin, A. P. Maxwell, and P. G. Johnston Warning Flags for Erythropoiesis-Stimulating Agents and Cancer-Associated Anemia Oncologist, April 1, 2007; 12(4): 362 - 365. [Full Text] [PDF]
|
|
|
|
 |
|
 D. P Steensma Erythropoiesis stimulating agents BMJ, March 31, 2007; 334(7595): 648 - 649. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
